You working on:

• A specific route of administration,
• A complex distribution,
• A pediatric indication,
• A pro-drug,
• Identification of active metabolites,
• NHP (Non Human Primates) models,
• Special populations,
• A repositioning strategy...

Our experts are ready to support you

Our highly qualified experts are available to provide their expertise and advise you on a wide range of pharmacometric topics.

• Consolidate the choice of “FiH dose” and dose ranging in a phase I/II clinical trial
• Develop your candidate from the physico-chemical characterization & in vitro test (possibility of reaching an exposure threshold in humans)
• Predict the Pharmacokinetic of the candidate with different doses and dosing regimens
• Determine the best trade-off between the number of samples and the cost
• Predict the risk of QTc prolongation
• Identify the dose ranges to be used for in vivo studies
• Evaluate “in silico” drug–drug interactions to de-risk as early as preclinical development, and potentially a “biowaiver” in the clinic
• Reduce the number of clinical trials